Calprotectin in Bile: A Disease Severity Marker in Patients With Primary Sclerosing Cholangitis
Calprotectin in Bile: A Disease Severity Marker in Patients With Primary Sclerosing Cholangitis
复制标题
胆汁中的钙卫蛋白：原发性硬化性胆管炎患者的疾病严重程度标志物
DOI：
10.1097/mcg.0000000000000042
复制
发表时间：
2014
影响因子：
2.9
通讯作者：
T. Lankisch
中科院分区：
文献类型：
--
作者：
T. Voigtländer;J. Wlecke;A. Negm;H. Lenzen;M. Manns;T. Lankisch
目的：我们的目的是评估钙卫蛋白在原发性硬化性胆管炎（PSC）患者血清和胆汁中的诊断潜力。背景：PSC是一种病因不明的慢性胆汁淤积性肝病。其特征在于胆管的进行性炎症和纤维化，导致胆汁性肝硬化并最终导致肝功能衰竭。疾病活动性和严重程度的可靠标志物仍然缺乏。钙卫蛋白亚基是炎症性肠病的粪便炎症标志物，最近在胆汁中发现。研究项目：采用酶联免疫吸附法测定了56例原发性胆管癌（PSC）、13例胆管癌（CC/PSC）、30例胆管癌（CC）和73例胆管结石患者血清和胆汁中钙卫蛋白的含量。PSC患者通过马约风险评分（MRS）进行分类，以表征疾病严重程度。结果：胆汁中存在钙卫蛋白，且PSC患者胆汁中钙卫蛋白浓度显著高于对照组（P<0.05）。通过MRS对PSC患者进行分层，MRS高组胆汁中钙卫蛋白水平显著升高（P<0.05）。钙卫蛋白与MRS呈显著相关（P<0.05）。PSC患者是否存在炎症性肠病并不改变胆汁中钙卫蛋白的水平。血清AP与胆汁中钙卫蛋白水平显著相关（P=0.013）。其他肝脏相关参数无显著相关性。相比之下，血清钙卫蛋白水平在CC患者中显著较高，但与PSC或疾病活动/严重程度无关。结论：胆汁中钙卫蛋白是PSC患者一个有前景的疾病标志物，具有潜在的预后价值。
Goals: Our aim was to evaluate the diagnostic potential of calprotectin in serum and bile of patients with primary sclerosing cholangitis (PSC). Background: PSC is a chronic cholestatic liver disease of unknown etiology. It is characterized by progressive inflammation and fibrosis of the bile ducts leading to biliary cirrhosis and eventually liver failure. Reliable markers for disease activity and severity are still lacking. Subunits of calprotectin, a fecal marker of inflammation in inflammatory bowel disease, have been recently identified in bile. Study: Calprotectin was measured in patients with PSC (n=56), cholangiocarcinoma (CC) complicating PSC (CC/PSC) (n=13), CC (n=30), and bile duct stones in bile (n=38) and serum (n=73) by enzyme-linked immunosorbent assay in a cross-sectional study. PSC patients were categorized by the Mayo risk score (MRS) to characterize the disease severity. Results: Calprotectin is present in bile, and the median concentration was significantly higher in PSC patients (P<0.05). Stratification of PSC patients by MRS showed significantly elevated calprotectin levels in bile in the MRS-high group (P<0.05). Calprotectin and MRS correlated significantly (P<0.05). The presence or absence of inflammatory bowel disease in PSC patients did not alter calprotectin levels in bile. Serum AP and calprotectin in bile correlated significantly (P=0.013). No significant correlation was found for other liver-related parameters. In contrast, serum calprotectin levels were significantly higher in patients with CC, but there was no association with PSC or disease activity/severity. Conclusions: Calprotectin in bile is a promising disease marker in patients with PSC with a potential prognostic value.
影响因子：
8.9
作者：
W. R. Kim;T. Therneau;R. Wiesner;J. Poterucha;J. Benson;M. Malinchoc;N. LaRusso;K. Lindor;E. Dickson
通讯作者：
W. R. Kim;T. Therneau;R. Wiesner;J. Poterucha;J. Benson;M. Malinchoc;N. LaRusso;K. Lindor;E. Dickson
DOI：
10.1152/ajpgi.00227.2012
发表时间：
2012-11-01
影响因子：
4.5
作者：
Syal, Gaurav;Fausther, Michel;Dranoff, Jonathan A.
通讯作者：
Dranoff, Jonathan A.